Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 24650884)

1.

Gold nanoparticles and radiofrequency in experimental models for hepatocellular carcinoma.

Raoof M, Corr SJ, Zhu C, Cisneros BT, Kaluarachchi WD, Phounsavath S, Wilson LJ, Curley SA.

Nanomedicine. 2014 Aug;10(6):1121-30. doi: 10.1016/j.nano.2014.03.004. Epub 2014 Mar 17.

PMID:
24650884
2.

Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles.

Glazer ES, Zhu C, Massey KL, Thompson CS, Kaluarachchi WD, Hamir AN, Curley SA.

Clin Cancer Res. 2010 Dec 1;16(23):5712-21. doi: 10.1158/1078-0432.CCR-10-2055.

3.

Hyperthermia inhibits recombination repair of gemcitabine-stalled replication forks.

Raoof M, Zhu C, Cisneros BT, Liu H, Corr SJ, Wilson LJ, Curley SA.

J Natl Cancer Inst. 2014 Aug 15;106(8). pii: dju183. doi: 10.1093/jnci/dju183. Print 2014 Aug.

PMID:
25128695
4.

Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo.

Khan JA, Kudgus RA, Szabolcs A, Dutta S, Wang E, Cao S, Curran GL, Shah V, Curley S, Mukhopadhyay D, Robertson JD, Bhattacharya R, Mukherjee P.

PLoS One. 2011;6(6):e20347. doi: 10.1371/journal.pone.0020347. Epub 2011 Jun 27.

5.

Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics.

Kudgus RA, Szabolcs A, Khan JA, Walden CA, Reid JM, Robertson JD, Bhattacharya R, Mukherjee P.

PLoS One. 2013;8(3):e57522. doi: 10.1371/journal.pone.0057522. Epub 2013 Mar 6.

6.

Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles.

Curley SA, Cherukuri P, Briggs K, Patra CR, Upton M, Dolson E, Mukherjee P.

J Exp Ther Oncol. 2008;7(4):313-26.

PMID:
19227011
7.

Stability of antibody-conjugated gold nanoparticles in the endolysosomal nanoenvironment: implications for noninvasive radiofrequency-based cancer therapy.

Raoof M, Corr SJ, Kaluarachchi WD, Massey KL, Briggs K, Zhu C, Cheney MA, Wilson LJ, Curley SA.

Nanomedicine. 2012 Oct;8(7):1096-105. doi: 10.1016/j.nano.2012.02.001. Epub 2012 Feb 17.

8.

SM5-1-conjugated PLA nanoparticles loaded with 5-fluorouracil for targeted hepatocellular carcinoma imaging and therapy.

Ma X, Cheng Z, Jin Y, Liang X, Yang X, Dai Z, Tian J.

Biomaterials. 2014 Mar;35(9):2878-89. doi: 10.1016/j.biomaterials.2013.12.045. Epub 2014 Jan 8.

9.

Radiofrequency field-induced thermal cytotoxicity in cancer cells treated with fluorescent nanoparticles.

Glazer ES, Curley SA.

Cancer. 2010 Jul 1;116(13):3285-93. doi: 10.1002/cncr.25135.

10.

Pancreatic carcinoma cells are susceptible to noninvasive radio frequency fields after treatment with targeted gold nanoparticles.

Glazer ES, Massey KL, Zhu C, Curley SA.

Surgery. 2010 Aug;148(2):319-24. doi: 10.1016/j.surg.2010.04.025. Epub 2010 Jun 11.

11.

Luciferase-based protein denaturation assay for quantification of radiofrequency field-induced targeted hyperthermia: developing an intracellular thermometer.

Raoof M, Zhu C, Kaluarachchi WD, Curley SA.

Int J Hyperthermia. 2012;28(3):202-9. doi: 10.3109/02656736.2012.666318.

12.

Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation.

Buchsbaum DJ, Bonner JA, Grizzle WE, Stackhouse MA, Carpenter M, Hicklin DJ, Bohlen P, Raisch KP.

Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1180-93.

PMID:
12419447
13.

Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human hepatocellular and gastric cancer xenografts.

Teicher BA, Menon K, Alvarez E, Liu P, Shih C, Faul MM.

In Vivo. 2001 May-Jun;15(3):185-93.

PMID:
11491013
14.

Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.

Patra CR, Bhattacharya R, Wang E, Katarya A, Lau JS, Dutta S, Muders M, Wang S, Buhrow SA, Safgren SL, Yaszemski MJ, Reid JM, Ames MM, Mukherjee P, Mukhopadhyay D.

Cancer Res. 2008 Mar 15;68(6):1970-8. doi: 10.1158/0008-5472.CAN-07-6102.

15.
16.

Gold nanoparticles conjugated with cisplatin/doxorubicin/capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cells.

Tomuleasa C, Soritau O, Orza A, Dudea M, Petrushev B, Mosteanu O, Susman S, Florea A, Pall E, Aldea M, Kacso G, Cristea V, Berindan-Neagoe I, Irimie A.

J Gastrointestin Liver Dis. 2012 Jun;21(2):187-96.

17.

Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy.

Shenoi MM, Iltis I, Choi J, Koonce NA, Metzger GJ, Griffin RJ, Bischof JC.

Mol Pharm. 2013 May 6;10(5):1683-94. doi: 10.1021/mp300505w. Epub 2013 Apr 17.

18.

Therapeutic effect of a multi-targeted imidazolium compound in hepatocellular carcinoma.

Gopalan B, Narayanan K, Ke Z, Lu T, Zhang Y, Zhuo L.

Biomaterials. 2014 Aug;35(26):7479-87. doi: 10.1016/j.biomaterials.2014.05.022. Epub 2014 Jun 6.

PMID:
24912819
20.

Evaluation of EGFR-targeted radioimmuno-gold-nanoparticles as a theranostic agent in a tumor animal model.

Kao HW, Lin YY, Chen CC, Chi KH, Tien DC, Hsia CC, Lin MH, Wang HE.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3180-5. doi: 10.1016/j.bmcl.2013.04.002. Epub 2013 Apr 10.

PMID:
23628334
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk